Myocardial infarct size reduction by the synergistic effect of hyperbaric oxygen and recombinant tissue plasminogen activator
- 1 October 1990
- journal article
- research article
- Published by Elsevier in American Heart Journal
- Vol. 120 (4) , 791-800
- https://doi.org/10.1016/0002-8703(90)90194-3
Abstract
No abstract availableThis publication has 27 references indexed in Scilit:
- Thrombolysis in myocardial infarction (TIMI) trial—Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinaseJournal of the American College of Cardiology, 1988
- Coronary thrombolysis with recombinant human tissue-type plasminogen activator.Circulation, 1984
- Improvement of regional myocardial metabolism after coronary thrombolysis induced with tissue-type plasminogen activator or streptokinase.Circulation, 1984
- Coronary thrombolysis with intravenously administered human tissue-type plasminogen activator produced by recombinant DNA technology.Circulation, 1984
- Clot-Selective Coronary Thrombolysis with Tissue-Type Plasminogen ActivatorScience, 1983
- Thrombolysis with human extrinsic (tissue-type) plasminogen activator in dogs with femoral vein thrombosis.Journal of Clinical Investigation, 1982
- Efforts to Limit the Size of Myocardial InfarctsAnnals of Internal Medicine, 1981
- Protective effect of hyperbaric oxygen for the temporary ischaemic myocardium. Macroscopic and histological dataCardiovascular Research, 1976
- A new catheter technique for producing experimental coronary thrombosis and selective coronary visualizationAmerican Heart Journal, 1972
- Hyperbaric oxygenation in the treatment of acute myocardial infarctionProgress in Cardiovascular Diseases, 1968